Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients dlvr.it/SkPCM2

Designed with implanters in mind. Precision. Control. Predictability. See what the Evolut™ FX System can do. Risk Info: bit.ly/3R5AbMV Find more details: bit.ly/3kEr7UN #EvolutFX #TAVR

Feel the difference! The Evolut™ FX System is designed with a single-spine shaft for greater flexibility and improved deliverability. Risk Info: bit.ly/3R5AbMV Find more details: bit.ly/3kEr7UN #EvolutFX #TAVR

Only CoreValve™/Evolut™ TAVR has signficantly better valve performance and durability than SAVR at 5 years. Risk Info: bit.ly/3R5AbMV

Breaking: Evolut™ TAVR is the ONLY platform to show excellent valve performance in low-risk patients at 3 years. Risk Info: bit.ly/3R5AbMV

Where's the low-risk #TAVR data? Ours was just presented at #ACC23 with a simultaneous publication in the Journal of the American College of Cardiology. Check out the key takeaways! bit.ly/3LagWla bit.ly/3A8X8s5

Did you know? Up to 30% of #aorticstenosis cases match the definition of low-flow, low-gradient, where AVA ≤ 1.0 cm², but with gradients in a non-severe range. Detecting severe AS in LF-LG patients isn’t always clear. Visit us for details: medtronic.com/us-en/healthca…

Your patients may mistake heart valve disease symptoms for normal signs of aging—so they don’t speak up. Silence is NOT golden. Help your patients with aortic stenosis learn what to watch for.

For symptomatic SAS patients, an urgent evaluation is everything. Anomalies like SVi< 35mL/m2, AVA is ≤ 1 cm², and LVEF < 50% could point to low-flow, low-gradient severe aortic stenosis. See the ACC/AHA Guidelines and visit us for details: medtronic.com/us-en/healthca…

Our AS TAVR app gives you tools, videos, and more to teach patients about aortic stenosis and TAVR in ways that work best for them. Download today: medtronic.com/us-en/healthca… What is most helpful for your patients? Tell us in the comments! #cardiotwitter

The heart team at @SaintFrancisMem recommended #TAVR for Gary so he could get back to the activities he loves faster. Download his story and other educational resources for your patients with #aorticstenosis here: bit.ly/3HlDkpt Risks: bit.ly/40O3OXF

The best durability: our #TAVR platform had significantly better BVD at 5 yrs vs. SAVR, driven by 2x lower SVD (2.2% TAVR vs. 4.4% SAVR, p<0.01) & 3x lower severe PPM. bit.ly/3ooHqqC Risk info: bit.ly/41UNZ1L. Devices: CoreValve 88%/Evolut R 12%

Join us tomorrow at #TVT2023. Our expert panel will discuss design, procedural outcomes, and performance focusing on the Evolut™ FX #TAVR system. bit.ly/3qyLGEI

Breaking today at #TCT2023: Evolut™ #TAVR system shows excellent valve performance in low-risk patients with a 26% reduction in hazard for death or disabling stroke at 4 years. Risk info: bit.ly/46UTL6I

The next highly-anticipated late-breaker at #TCT2023: Michael Reardon, MD, shares 4-year data from the Evolut Low Risk Trial Cardiovascular Research Foundation TCT Conference Medtronic #TAVR #Cardiology

The Evolut Low Risk Trial included 1,414 low-risk patients randomized to receive #TAVR with a Medtronic Evolut valve or SAVR. After 4 years, TAVR was linked to lower rates of all-cause mortality and disabling stroke as well as improved hemodynamics #Cardiology #TCT2023

Medtronic Dr. Reardon emphasized that this is just a 4-year update of an ongoing #TAVR trial. He said he has seen many valves start off strong in the past, but then the performance falls off after 6 or 7 years. #TCT2023 #Cardiology

Dr. Michael Reardon presents late-breaking EVOLUT results at TCT #Sponsored utm.guru/uf4i5

Happy birthday to young Andy Dalton one of the greats! Beat the Texans!

Highs, lows, and everything in between. Max Duggan learned to enjoy the process and the journey. Underdog